9 EYEPOINT® PHARMACEUTICALS Investor Presentation September 28, 2022 Forward-Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdi ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - President and Chief Executive Officer Jay Duker - Chief Operating Officer Scott Jones - Chief Commercial Officer Conference Call Participants Stacy Ku - Cowen Eddie Hickman - Guggenheim Partners Jennifer Kim - Cantor Yale Jen - Laidlaw Yi Chen - H.C. Wainwright Operator Good morning. My name is Michelle, and I’ll be your conferenc ...

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation March 2022 Forward Looking Statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limite ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2774444 (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (EYPT Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants George Elston - CFO Nancy Lurker - President & CEO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Georgi Yordanov - Cowen Eddie Hickman - Guggenheim Securities Yi Chen - H.C. Wainwright Yale Jen - Laidlaw & Company Operator Good morning. My name is Jonathan. And I will be your conference operator today. At this time, I wo ...

1 | EYEPOINT PHARMACEUTICALS Delivering Innovation to the Eye Investor Presentation November 2021 Forward looking statements Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not lim ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 000-51122 EyePoint Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of in ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants George O. Elston - CFO & Head, Corporate Development Nancy Lurker - President & CEO Jay Duker - COO Scott Jones - Chief Commercial Officer Conference Call Participants Unidentified Analyst - Cowen and Company Jennifer Kim - Cantor Fitzgerald Yatin Suneja - Guggenheim Partners Yale Jen - Laidlaw & Company Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by. Welc ...